NCT00621153

Candesartan Effect in Second Stage Arterial Hypertension

Open-label, Randomised, 2-Arm Parallel Group, Multicentre, 8-week, Phase IV Study to Assess the Antihypertensive Efficacy and Safety of the Candesartan Cilexetil 16 mg and Hydrochlorothiazide 12.5 mg Combination Therapy in Comparison With Candesartan 16 mg Monotherapy in Hypertensive Adults

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 214 (actual)
• Sponsor: AstraZeneca · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

To compare the changes in mean sitting DBP from baseline after 4 weeks of therapy with either candesartan cilexetil/HCT combination therapy or candesartan cilexetil monotherapy regimen

Conditions

• Stage II Hypertension

Interventions

Type	Name	Description
DRUG	Candesartan Cilexetil	Candesartan Cilexetil 16 mg oral
DRUG	Hydrochlorothiazide	Hydrochlorothiazide 12.5 mg
DRUG	Candesartan Cilexetil	Candesartan Cilexetil 32 mg oral

Timeline

• Start date: 2008-02-01
• Primary completion: 2009-03-01
• Completion: 2009-03-01
• First posted: 2008-02-22
• Last updated: 2010-03-23
• Results posted: 2010-03-23

Locations

1 site across 1 country: South Korea